<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction extraction-result-73 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extracted Data Details for extraction-result-73</h1>

        <div class="section">
            <h2>Extracted Data (Header)</h2>
            <div class="info-section">
                <p><strong>Extraction ID:</strong> extraction-result-73</p>
                <p><strong>Extraction Schema Used (ID):</strong> <a href="../schemas/extraction-schema-2.html">extraction-schema-2</a></p>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in different ethnic or geographic populations, particularly comparing East Asian and non-Asian populations, along with any proposed mechanisms, risk factors, or explanations for these differences.</div>
                <p><strong>Paper ID:</strong> paper-196610790</p>
                <p><strong>Paper Title:</strong> Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma</p>
                <p><strong>Paper Abstract:</strong> Purpose The purpose of this study was to investigate the relationship between epidermal growth factor receptor (EGFR) gene mutation and clinicopathological features of lung adenocarcinoma, and the prognostic and therapeutic value of EGFR. Methods EGFR gene mutations were detected in 424 patients with lung adenocarcinoma by amplification refractory mutation system (ARMS). Results The total EGFR gene mutation rate was 55.2% (234/424) and EGFR gene mutation rates were statistically different in gender, smoking status, and pathological degree (P<0.05). The overall survival (OS) time of lung adenocarcinoma patients with mutation of exon 18 was lower than those with mutation of exon 19 and exon 21 (both P<0.05), but no significant difference was seen between those with mutation of exon 19 and exon 21 (P>0.05). Among 424 cases of lung adenocarcinoma, multivariate analysis showed that EGFR gene mutation, age, gender, clinical stages, and pathological degree (P<0.05) were statistically significant prognostic factors. In multivariate analysis, prognostic factors of patients with EGFR gene mutation were associated with EGFR-TKI treatment, surgery treatment, pathological degree, clinical stages, and age (P<0.05), whereas in patients without EGFR gene mutation, prognostic factors were related to surgery treatment, pathological degree, clinical stages, gender, age, and smoking status (P<0.05). Conclusion The OS time of patients with mutation of exon 18 was lower than those of exon 19 and exon 21. EGFR-TKI treatment was an independent positive predictor in patients with EGFR gene mutation. Surgery treatment, age, clinical stages, and pathological degree were independent prognostic factors in Chinese patients with lung adenocarcinoma no matter whether with EGFR gene mutation or not.</p>
                <p><strong>Cost:</strong> 0.008</p>
            </div>
        </div>

        <div class="section">
            <h2>Extracted Data (Details)</h2>
            <div class="extraction-instance-container" id="e73.0">
                <h3 class="extraction-instance">Extracted Data Instance 0 (e73.0)</h3>
                <div class="extraction-query"><strong>Extraction Query:</strong> Extract any mentions of EGFR mutation frequencies in different ethnic or geographic populations, particularly comparing East Asian and non-Asian populations, along with any proposed mechanisms, risk factors, or explanations for these differences.</div>
                <table>
                    <thead>
                        <tr>
                            <th style="width: 30%;">Field</th>
                            <th style="width: 70%;">Value</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>name_short</strong></td>
                            <td>EGFR-mutant Chinese cohort</td>
                        </tr>
                        <tr>
                            <td><strong>name_full</strong></td>
                            <td>Chinese lung adenocarcinoma cohort (The Second Xiangya Hospital, Central South University)</td>
                        </tr>
                        <tr>
                            <td><strong>brief_description</strong></td>
                            <td>A retrospective study of 424 pathologically confirmed lung adenocarcinoma patients from Changsha, Hunan, China, reporting EGFR mutation prevalence, exon-specific distribution, clinicopathological associations, and prognostic implications including response to EGFR-TKIs.</td>
                        </tr>
                        <tr>
                            <td><strong>citation_title</strong></td>
                            <td>Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>mention_or_use</strong></td>
                            <td>use</td>
                        </tr>
                        <tr>
                            <td><strong>study_population</strong></td>
                            <td>Chinese patients (East Asian) â€” 424 lung adenocarcinoma cases treated at The Second Xiangya Hospital of Central South University, Changsha, Hunan, People's Republic of China</td>
                        </tr>
                        <tr>
                            <td><strong>egfr_mutation_frequency</strong></td>
                            <td>55.2% overall (234/424). Exon-specific: exon 18 = 2.0%; exon 19 = 48.0%; exon 20 = 5.0%; exon 21 = 42.0%; double mutations = 3.0%. (Most common: exon 19 deletions and exon 21 L858R.)</td>
                        </tr>
                        <tr>
                            <td><strong>comparison_populations</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>specific_mutation_types</strong></td>
                            <td>Exon 19 deletions (19del), exon 21 L858R, exon 18 (G719X), exon 21 L861Q, exon 20 insertions and T790M (resistance), plus observed double mutations (18+21, 19+20, 20+21).</td>
                        </tr>
                        <tr>
                            <td><strong>smoking_status_association</strong></td>
                            <td>EGFR mutations were more frequent in nonsmokers (66.9% in nonsmokers vs 34.2% in smokers). However, logistic regression did not find smoking an independent predictor of EGFR mutation (likely confounded by gender); the authors note possible misclassification (second-hand smoke) and inconsistent smoking definitions.</td>
                        </tr>
                        <tr>
                            <td><strong>environmental_factors</strong></td>
                            <td>Tobacco smoking discussed as a general lung cancer risk factor in the introduction; no other environmental exposures (e.g., air pollution, cooking oil fumes, radon) were proposed as explanations for ethnic differences in this paper. The authors note possible second-hand smoke misclassification among 'nonsmokers.'</td>
                        </tr>
                        <tr>
                            <td><strong>genetic_factors</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>biological_mechanisms</strong></td>
                            <td><span class="empty-note">null</span></td>
                        </tr>
                        <tr>
                            <td><strong>lung_cancer_subtype</strong></td>
                            <td>Lung adenocarcinoma</td>
                        </tr>
                        <tr>
                            <td><strong>demographic_factors</strong></td>
                            <td>Higher EGFR mutation rates in females (73.9% female vs 37.3% male). No significant association with age or clinical stage in this cohort. The paper notes higher prevalence among nonsmokers and better differentiation (well/moderate) tumors.</td>
                        </tr>
                        <tr>
                            <td><strong>proposed_explanation</strong></td>
                            <td>The paper does not propose molecular or population-genetic mechanisms for higher EGFR mutation prevalence in East Asians; it attributes observed associations primarily to clinicopathological correlates (female sex, nonsmoking status, well/moderate differentiation) and highlights potential confounding (notably between gender and smoking). The authors emphasize methodological issues (inconsistent smoking definitions, possible second-hand smoke exposure) and call for larger samples to clarify associations.</td>
                        </tr>
                        <tr>
                            <td><strong>counterevidence_or_confounds</strong></td>
                            <td>Logistic regression found EGFR mutation independently associated with gender and pathological degree but not smoking status, suggesting smoking may be a confounder (related to gender). The authors note possible misclassification of smoking (second-hand smoke counted as nonsmoker) and lack of uniform smoking-status assessment; they recommend larger studies to resolve these issues. No direct non-Asian comparator data are provided within the paper.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <div class="section">
            <h2>Potentially Relevant New Papers (mentioned by this paper)</h2>
            <ol>
                <li>Epidermal growth factor receptor mutations in lung cancer <em>(Rating: 2)</em></li>
                <li>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib <em>(Rating: 2)</em></li>
                <li>High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/ TTF-1 expressions, and clinical features <em>(Rating: 2)</em></li>
                <li>Associations between epidermal growth factor receptor mutations and histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification in Chinese patients <em>(Rating: 2)</em></li>
                <li>Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer <em>(Rating: 1)</em></li>
                <li>Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer <em>(Rating: 1)</em></li>
            </ol>
        </div>

        </div>

    </div>
</body>
</html>